NYSE: ABTAbbott Laboratories Revenue
Abbott Laboratories revenue was $43.84B for the trailing 12 months ending Sep 30, 2025, with 142.4% growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $11.4B, up 2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ABT annual revenue was $42.0B, with 4.6% growth year-over-year.
ABT past revenue growth
How has ABT's revenue growth performed historically?
Company
6.37%
Industry
10.95%
Market
20.37%
ABT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ABT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ABT's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
ABT revenue history
Current Revenue
$43.8B
Current Earnings
$14.0B
Current Profit Margin
31.9%
ABT's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance
Be the first to know when ABT announces revenue.
ABT Revenue History By Year
| ABT Yearly Revenue | ABT Revenue | ABT Change | ABT Revenue Growth |
|---|---|---|---|
| 2024-12-31 | $41.95B | $1.84B | +4.59% |
| 2023-12-31 | $40.11B | -$3.54B | -8.12% |
| 2022-12-31 | $43.65B | $578.00M | +1.34% |
| 2021-12-31 | $43.08B | $8.47B | +24.47% |
| 2020-12-31 | $34.61B | $2.70B | +8.48% |
| 2019-12-31 | $31.90B | $1.33B | +4.34% |
| 2018-12-31 | $30.58B | $3.19B | +11.64% |
| 2017-12-31 | $27.39B | $6.54B | +31.35% |
| 2016-12-31 | $20.85B | $448.00M | +2.20% |
| 2015-12-31 | $20.41B | $158.00M | +0.78% |
| 2014-12-31 | $20.25B | $590.00M | +3.00% |
| 2013-12-31 | $19.66B | $607.00M | +3.19% |
| 2012-12-31 | $19.05B | -$2.36B | -11.01% |
| 2011-12-31 | $21.41B | -$13.76B | -39.13% |
| 2010-12-31 | $35.17B | $4.40B | +14.31% |
| 2009-12-31 | $30.76B | $1.24B | +4.19% |
| 2008-12-31 | $29.53B | $3.61B | +13.94% |
| 2007-12-31 | $25.91B | $3.44B | +15.30% |
| 2006-12-31 | $22.48B | $138.51M | +0.62% |
| 2005-12-31 | $22.34B | $2.66B | +13.51% |
| 2004-12-31 | $19.68B | $2.40B | +13.89% |
| 2003-12-31 | $17.28B | $2.00B | +13.09% |
| 2002-12-31 | $15.28B | -$1.01B | -6.18% |
| 2001-12-31 | $16.29B | $2.54B | +18.47% |
| 2000-12-31 | $13.75B | $568.29M | +4.31% |
| 1999-12-31 | $13.18B | $664.89M | +5.31% |
| 1998-12-31 | $12.51B | $623.45M | +5.24% |
| 1997-12-31 | $11.89B | $875.82M | +7.95% |
| 1996-12-31 | $11.01B | $1.00B | +10.00% |
| 1995-12-31 | $10.01B | $856.19M | +9.35% |
| 1994-12-31 | $9.16B | $748.17M | +8.90% |
| 1993-12-31 | $8.41B | $555.93M | +7.08% |
| 1992-12-31 | $7.85B | $975.32M | +14.18% |
| 1991-12-31 | $6.88B | N/A | N/A |
Abbott Laboratories Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.